Diabetes in Medical Technology

Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership

- Program Focuses on Expanding Pipeline of Drugs For People with Type 1 Diabetes - NEW YORK, Aug. 5 /PRNewswire-USNewswire/ -- The Juvenile Diabetes Research Foundation said today that it has entered into a novel collaborative research agreement with the Genomics Institute of th...

S.C. Medical Home Pilot for Diabetes Enrolls 1,110

COLUMBIA, S.C. and NORTH CHARLESTON, S.C., July 27 /PRNewswire-USNewswire/ -- A patient centered medical home pilot project that could become a model for South Carolina has completed its first quarter with 1,110 patients enrolled. It is also attracting the attention of S.C. physicians no...

Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions

NEW ORLEANS and CARLSBAD, Calif., June 9 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced today that Isis' antisense drugs were highlighted with eight presentations (including three oral talks and two late-breaking posters) during the American Diabetes Association's...

FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSK's Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight

ROCKVILLE, Md. , June 8 /PRNewswire-FirstCall/ -- Attached is a press release issued yesterday by GlaxoSmithKline (GSK), regarding new Phase 2 data for Syncria(R) (albiglutide) presented at the American Diabetes Association 69th Scientific Sessions in New Orleans. (Logo: http://www.newsco...

Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association

Oral Presentation Details Dose Optimization of Pre-Clinical Otelixizumab Surrogate NEW ORLEANS, June 8 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for immune-mediated diseases, today presented results from a pre-clinica...

Research: Popular Diabetes Medications Associated with Increase in Bone Fractures

FRANKLIN LAKES, N.J., June 8, /PRNewswire-FirstCall/ -- Research presented at the American Diabetes Association's 69th Scientific Sessions points to increased risk for people with diabetes associated with two widely used drug classes; while another study shed new light on a different class of drug...

SCAI Statement on the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation With Diabetes Trial) Presented at the American Diabetes Association (ADA) Annual Scientific Sessions and Published in The New England Journal of Medicine

WASHINGTON, June 7 /PRNewswire/ -- BARI-2D is a useful and focused trial that builds on the body of scientific knowledge physicians use to provide the best possible care for diabetic patients with chronic stable angina and to evaluate their treatment options. The Society for Cardiovascular Angiog...

Study Shows GSK's Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control and Reduces Weight

LONDON, RESEARCH TRIANGLE PARK, N.C., and NEW ORLEANS, June 7 /PRNewswire-FirstCall/ -- New Phase II data presented today at the American Diabetes Association 69th Scientific Sessions in New Orleans show that the investigational type 2 diabetes treatment Syncria(R) (albiglutide) significantly redu...

Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients

Latest data on ultra rapid acting insulin presented at the American Diabetes Association's 69th Scientific Sessions NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- The findings of two 52-week studies show that the investigational ultra rapid acting insulin AFRESA(R) (insulin human [rDNA or...

Boehringer Ingelheim Unveils Diabetes Pipeline

RIDGEFIELD, Conn., June 6 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced its pipeline of oral antidiabetic compounds, establishing itself in the type 2 diabetes therapeutic area. The Company is investigating compounds in Phase II and Phase III clinical development worl...

AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA

Two-year study presented at the American Diabetes Association's 69th Scientific Sessions shows investigational product comparable to standard insulin therapy in pulmonary function tests NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- AFRESA(R) (insulin human [rDNA origin]) Inhalation Powder is ...

Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines

RECORD trial also demonstrates durable blood sugar control over time with Avandia LONDON, RESEARCH TRIANGLE PARK, N.C., and NEW ORLEANS, June 5 /PRNewswire/ -- Clinical trial results presented today at the American Diabetes Association annual meeting show that overall rates of cardiovascular ...

Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Association's 69th Scientific Sessions

- Late-Breaking Abstract Accepted - SAN DIEGO, June 1, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) announced today that a late-breaking abstract of its lorcaserin Phase 3 BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) tr...

InteKrin Therapeutics to Present at the 2009 American Diabetes Association Annual Meeting

LOS ALTOS, Calif., May 28 /PRNewswire/ -- InteKrin Therapeutics, Inc. announced today it will present Phase 2a clinical data for INT131, a Selective PPAR Modulator (SPPARM), at the American Diabetes Association annual meeting in New Orleans Saturday, June 6, 2009 during the "Novel Diabetes Therapi...

Taking a Hard-Line Approach to Cardiovascular Risks in the Diabetes Patient

HOUSTON, May 18 /PRNewswire-USNewswire/ -- When treating the diabetes patient, doctors discussed how a "one size fits all" approach to testing is not enough to reveal an individual's risk for cardiovascular disease Saturday at the American Association of Clinical Endocrinologists (AACE) 18th Ann...

Juvenile Diabetes Research Foundation to Honor Duane DeSisto of Insulet Corporation and Senator Edward M. Kennedy at 27th Annual Hearts & Heroes Gala

WELLESLEY, Mass., May 15 /PRNewswire/ -- The New England Chapter - Bay State Branch of the Juvenile Diabetes Research Foundation (JDRF), the leader in setting the agenda for diabetes research worldwide and the largest charitable funder and advocate of type 1 research, will host its 27th Annual Hea...

Pistachios Offer Protective Benefits Against Heart Disease, Type II Diabetes and Obesity

Research Presented at Experimental Biology 2009 Reveals Cardiovascular and Glycemic Control Benefits of Pistachios NEW ORLEANS, April 22 /PRNewswire/ -- Pistachios are much more than a great-tasting snack. The little green nuts may do more for your heart, blood sugar and waistline than many ...

Joint Statement from the American Diabetes Association and American Association of Clinical Endocrinologists on the NICE-SUGAR Study on Intensive Versus Conventional Glucose Control in Critically Ill Patients

Response to March 24 article in the New England Journal of Medicine ALEXANDRIA, Va. and JACKSONVILLE, Fla., March 24 /PRNewswire-USNewswire/ -- A study published online today in the New England Journal of Medicine suggests that intensive blood glucose (sugar) control for critical ...

Spherix Postpones 2009 Annual Shareholders Meeting to Share Interim Diabetes Clinical Trial Data

INTERIM DATA FROM PHASE 3 CLINICAL TRIAL FOR NATURLOSE(R) ANTICIPATED BY FALL BETHESDA, Md., March 11 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX ), an innovator in biotechnology and a provider of technical and regulatory consulting services to food, supplement, biotechnolo...

Pioneering Diamyd(R) Study to Prevent Childhood Diabetes Approved

STOCKHOLM, March 4 /PRNewswire-FirstCall/ -- Diamyd Medical announces today that the Swedish Medical Products Agency has approved a study with the Diamyd(R) diabetes vaccine in children with high risk to develop type 1 diabetes. (Logo: http://www.newscom.com/cgi-bin/prnh/20080314/29719...

February 2009 Mayo Clinic Women's HealthSource Highlights Diabetes and Heart Disease, Going Vegetarian and Tinnitus

Diabetes and Heart Disease: Risk Intertwined ROCHESTER, Minn., Feb. 4 /PRNewswire-USNewswire/ -- Here are highlights from the February issue of Mayo Clinic Women's HealthSource . You may cite this publication as often as you wish. Mayo Clinic Women's HealthSource attribution is required...

Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals

SAN DIEGO, Dec. 15 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) announced today that Ortho-McNeil-Janssen Pharmaceuticals, Inc. (Ortho-McNeil) initiated under their partnership a first-in-human Phase 1 clinical trial of APD597, a novel oral drug candidate discovered by A...

Epidemics of Both Type 1 Diabetes (Insulin Dependent) and Type 2 Diabetes (Obesity Related) Are Linked to Immunization

BALTIMORE, Dec. 10 /PRNewswire/ -- Data by Dr. J. Bart Classen published this week in Diabetes & Metabolic Syndrome: Clinical Research & Reviews provides further evidence that epidemics of type 2 diabetes/obesity/metabolic syndrome, like type 1 diabetes, are linked to immunization. Class...

Overweight Siblings of Children With Type 2 Diabetes Likely to Have Abnormal Blood Sugar Levels

PHILADELPHIA, Dec. 9 /PRNewswire-USNewswire/ -- Overweight siblings of children with type 2 diabetes are four times more likely to have abnormal glucose levels compared to other overweight children. Because abnormal glucose levels may indicate risk for diabetes or diabetes itself, these children ...

Patient Recruitment Begins in India for Phase 3 Diabetes Trial

BETHESDA, Md., Nov. 7 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX ) reported that patient recruitment for its Phase 3 clinical trial of its potential type 2 diabetes drug, Naturlose(R), has begun in India. Expectations for India are to provide more than 300 patients spread ac...

Opportunities to Highlight Type 1 Diabetes in November

Diabetes Awareness Month and World Diabetes Day BETHESDA, Md., Nov. 4 /PRNewswire-USNewswire/ -- -- Diabetes Awareness Month, in November, and World Diabetes Day (Nov. 14) present outstanding opportunities to educate the public about type 1 diabetes screening and promising res...

Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Society's Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)

JERUSALEM, November 4 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a developer of proprietary drug delivery systems, announced today that its poster entitled "Enteral Administration of Exenatide-4; Proof of Concept Pharmacodynamic Study in ...

TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program

NATICK, Mass. and WASHINGTON, Oct. 12 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced results from an analysis of nearly 7,500 patients from its TAXUS ARRIVE 1 and 2 registries, which are designed to confirm the performance of the TAXUS(R) Express2(TM) Pac...

Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin

PARIS, September 10 /PRNewswire-FirstCall/ -- - Abstracts 186 and 1003 Sanofi-aventis announced today that results from two studies, GINGER and LACE, presented at the 44th annual meeting of the European Association for the Study of Diabetes (EASD) demonstrated that a basal-bolus insulin re...

Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel

Sub-group analysis of landmark trial showed prasugrel substantially reduced risk of heart attack and stent thrombosis compared with clopidogrel among ACS patients with diabetes MUNICH, Germany, Aug. 31 /PRNewswire-FirstCall/ -- Patients who were diabetic and diagnosed with...

Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market

Owing to Well-Established and Effective Insulin-Based Therapies, Market Growth Will be Modest Through 2017, According to a New Report from Decision Resources WALTHAM, Mass., Aug. 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and adviso...

Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial

Milestone achievement triggers $15 million payment from collaborator GlaxoSmithKline CAMBRIDGE, Mass., Aug. 6 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for immune-mediated diseases, today a...

'Snapshots' of Eyes Could Serve as Early Warning of Diabetes or Diabetic Eye Disease, U-M Researchers Report

FA imaging, invented at U-M, measures metabolic stress in retina ANN ARBOR, Mich., July 14 /PRNewswire-USNewswire/ -- A new vision screening device, already shown to give an early warning of eye disease, could give doctors and patients a head start on treating diabetes and its vision complic...

Spherix Expands Phase 3 Naturlose Diabetes Trial Outside of the U.S.

BETHESDA, Md., July 14 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX ) reported that the Phase 3 clinical trial of its potential type 2 diabetes drug, Naturlose(R), will expand outside of the United States. Several countries with high prevalence of treatment-naive type II diabe...

Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology

FRANKLIN, Mass., July 14 /PRNewswire-FirstCall/ -- Echo Therapeutics (OTC Bulletin Board: ECTE) today announced publication of results from three pilot clinical studies of its Symphony Transdermal Continuous Glucose Monitoring (tCGM) System in the Journal of Diabetes Science and Technology. Th...

Video: Sanford Health's Journey to Cure Type 1 Diabetes Receives Major Boost

Historic $10 Million Gift Creates Fund for Sanford Project Chair SIOUX FALLS, S.D., July 10 /PRNewswire/ -- Sanford Health announced today it has received a $10 million gift from Todd and Linda Broin of Sioux Falls, SD to fund the chair of the Sanford Project. The gift for the Todd and Lin...

AlphaDetail AlphaPulse(TM): Most Practicing Physicians React Positively to FDA Panel's Recommendation for Additional Cardiovascular Safety Trials for New Diabetes Medications.

SAN MATEO, Calif., July 8 /PRNewswire/ -- After meeting on July 1st and 2nd an FDA advisory panel recommended that all new diabetes drugs should undergo trials to rule out cardiovascular risk. 85% of US cardiologists and 65% of US endocrinologists agree with this recommendation, according to A...

Novel Testosterone Gel Significantly Improves Insulin Sensitivity and Sexual Function in Hypogonadal Men With Type 2 Diabetes and Metabolic Syndrome

New Data Highlights the Need for Testosterone Screening in At-Risk Hypogonadal Men BEDMINSTER, N.J., June 17 /PRNewswire/ -- New data from a 12-month, international, multi-center study showed that treatment for low testosterone with Tostran(R), a topical, metered ...

Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials

- Positive Phase II Results of Roche and Ipsen's First Once-Weekly Human GLP-1 Presented at the American Diabetes Association Meeting - NUTLEY, N.J., June 10 /PRNewswire/ -- Roche and Ipsen's investigational type 2 diabetes drug taspoglutide (R1583) has been shown to provide significant im...

Isis Highlights Robust Drug Portfolio for Diabetes and Obesity at ADA Conference

- Oral presentation on the potent blood glucose lowering effect of SGLT2 antisense inhibitors in multiple preclinical models - Eight additional presentations highlight significant activity in eight new metabolic disease targets utilizing antisense SAN FRANCISCO and CARLSBA...